» Articles » PMID: 34884554

Mesenchymal Stem Cell-Derived Extracellular Vesicle: A Promising Alternative Therapy for Osteoporosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Dec 10
PMID 34884554
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is the chronic metabolic bone disease caused by the disturbance of bone remodeling due to the imbalance of osteogenesis and osteoclastogenesis. A large population suffers from osteoporosis, and most of them are postmenopausal women or older people. To date, bisphosphonates are the main therapeutic agents in the treatment of osteoporosis. However, limited therapeutic effects with diverse side effects caused by bisphosphonates hindered the therapeutic applications and decreased the quality of life. Therefore, an alternative therapy for osteoporosis is still needed. Stem cells, especially mesenchymal stem cells, have been shown as a promising medication for numerous human diseases including many refractory diseases. Recently, researchers found that the extracellular vesicles derived from these stem cells possessed the similar therapeutic potential to that of parental cells. To date, a number of studies demonstrated the therapeutic applications of exogenous MSC-EVs for the treatment of osteoporosis. In this article, we reviewed the basic back ground of EVs, the cargo and therapeutic potential of MSC-EVs, and strategies of engineering of MSC-EVs for osteoporosis treatment.

Citing Articles

Mesenchymal stem cells: Guardians of women's health.

Gao G, Li L, Li C, Liu D, Wang Y, Li C Regen Ther. 2024; 26:1087-1098.

PMID: 39582803 PMC: 11585475. DOI: 10.1016/j.reth.2024.10.011.


Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases.

Tang J, Wang X, Lin X, Wu C Cell Death Discov. 2024; 10(1):212.

PMID: 38697996 PMC: 11066013. DOI: 10.1038/s41420-024-01973-w.


Metabolic bone disorders and the promise of marine osteoactive compounds.

Carletti A, Gavaia P, Cancela M, Laize V Cell Mol Life Sci. 2023; 81(1):11.

PMID: 38117357 PMC: 10733242. DOI: 10.1007/s00018-023-05033-x.


New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).

Palanisamy C, Pei J, Alugoju P, Anthikapalli N, Jayaraman S, Veeraraghavan V Theranostics. 2023; 13(12):4138-4165.

PMID: 37554286 PMC: 10405853. DOI: 10.7150/thno.83066.


Canine Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Attenuate Atopic Dermatitis.

Cho B, Kim S, Kim S, Rhee B, Yoon J, Lee J Animals (Basel). 2023; 13(13).

PMID: 37444013 PMC: 10339941. DOI: 10.3390/ani13132215.


References
1.
Chen Y, Lu C, Ke C, Chiu S, Jeng F, Chang C . Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer's Disease Pathology and Improve Cognitive Deficits. Biomedicines. 2021; 9(6). PMC: 8225157. DOI: 10.3390/biomedicines9060594. View

2.
Basalova N, Sagaradze G, Arbatskiy M, Evtushenko E, Kulebyakin K, Grigorieva O . Secretome of Mesenchymal Stromal Cells Prevents Myofibroblasts Differentiation by Transferring Fibrosis-Associated microRNAs within Extracellular Vesicles. Cells. 2020; 9(5). PMC: 7290371. DOI: 10.3390/cells9051272. View

3.
Liu Y, Shan H, Zong Y, Lin Y, Xia W, Wang N . IKKe in osteoclast inhibits the progression of methylprednisolone-induced osteonecrosis. Int J Biol Sci. 2021; 17(5):1353-1360. PMC: 8040464. DOI: 10.7150/ijbs.57962. View

4.
Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

5.
Sun Q, Hao Q, Prasanth K . Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression. Trends Genet. 2017; 34(2):142-157. PMC: 6002860. DOI: 10.1016/j.tig.2017.11.005. View